BRIEF-FDA advisory panel backs J&J drug for multidrug-resistant TB

Wed Nov 28, 2012 4:36pm EST

Related Topics

Nov 28 (Reuters) - Johnson & Johnson : * FDA advisory panel, by 18 to 0 vote, says data supports efficacy of j&j

drug bedaquiline against multidrug-resistant tb - j&j * FDA advisory panel, by 11 to 7 vote, say data suggest safety of bedaquiline

tb drug - j&j

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.